1.Observation of the clinical effects of modified treatment with sijunzi decoction and shenqi pills for primary hypothyroidism
Chinese Journal of Primary Medicine and Pharmacy 2015;(17):2610-2612
Objective To observe the clinical curative effect of sijunzi decoction composite with shenqi pills in the treatment of spleen and kidney yang deficiency syndrome in patients with primary hypothyroidism(hypothyroid-ism).Methods 62 spleen kidney yang deficiency patients with hypothyroidism were randomly divided into 30 cases in the control group and 32 cases in the treatment group.Patients in the control group were given L-thyroxine tablets orally,once a day;patients in the treatment group were given sijunzi decoction combined with shenqi pills for decoc-tion,daily 1 agent,3 times a day orally,on the basis of the control treatment group.Two groups treatment cycle were 4 months,and the clinical efficacy of the two groups were observed.Results The treatment group total effective rate was 96.9%,which was higher than that in the control group 80.0%(χ2 =4.402,P<0.05);before and after treat-ment,TCMsyndrome scores were significantly decreased in the two groups (t=21.40,25.40,all P<0.01)and treatment group decreased more significantly(t=4.30,P<0.01 ).Before and after treatment,TSH,FT3,FT4 in the two groups were significantly improved (control group:t=5.31,1.14,4.13,treatment group:t=6.27,1.85,6.08,all P<0.01),and the degree of improvement in treatment group was more obvious compared with the control group (t=1.33,0.67,278,all P<0.05).Conclusion Sijunzi decoction and shenqi pills can significantly improve the clinical symptoms of primary hypothyroidism of spleen-kidney yang deficiency type in addition to thyroid function and blood lipid,indicating that this method is capable of achieving satisfactory clinical effects in treating primary hypothyroidism of spleen-kidney yang deficiency type.
2.ASSESSMENT OF REDUCING SUB-CLINICAL INFECTIONS OF TOXOPLASMA GONDII IN NEWBORN BABIES WITH PREVENTIVE TREATMENT
Haiyong HUA ; Qian XU ; Yonghua ZHOU ; Zhongquan XUE ; Xiaohon GU
Chinese Journal of Schistosomiasis Control 1989;0(04):-
Objective To explore the effect of reducing sub-clinical infections of Toxoplasma gondii in newborn babies with preventive treatment. Methods Forty-four infected pregnant women were treated in different period and their umbilical blood and/or placenta of their newborn babies were tested for IgG, IgM, cAg and DNA of Toxoplasma gondii. Results The positive rate of Toxoplasma DNA in umbilical blood was 37.8%(14/37). The lowest rate was found in the preventive treatment group with a significant difference compared with the group of general treatment. Conclusion Preventive treatment can reduce sub-clinical infection rate of newborn babies effectively.
3.Effects of Goserelin on Vascular Growth Factor and Immune Function of Rats with Prostatic Hyperplasia
Wei XI ; Bang XU ; Yonghua ZHANG ; Qian ZHAO ; Jinbing CHEN
China Pharmacy 2017;28(16):2205-2208
OBJECTIVE:To study the effects of goserelin on vascular growth factor and immune function of rats with prostatic hyperplasia. METHODS:Rats were selected to establish prostatic hyperplasia model and randomly divided into model group,gose-relin low-dose,medium-dose and high-dose groups (0.4,0.8,1.2 mg/kg);normal rats were selected as normal control group, with 10 rats in each group. Normal control group and model group were given normal saline intragastrically,and goserelin groups were given relevant dose of drugs intragastrically,once a day,for consecutive 25 days. The prostate volume,wet weight,prostatic index of rats were detected as well as positive cell area of VEGF,TGF-β1,FGF,CD4 and CD8 in prostate tissue. RESULTS:Compared with normal control group,prostate volume,wet weight,prostatic index,positive cell area of VEGF,TGF-β1,FGF, CD4 and CD8 were all increased in model group (P<0.05). Compared with model group,the above indexes of goserelin groups were all improved (P<0.05),especially those in medium-dose and high-dose groups were better than in low-dose group (P<0.05);there was no statistical significance between medium-dose group and high-dose group(P>0.05). CONCLUSIONS:Gosere-lin can relieve prostatic hyperplasia of rats,reduce the expression of VEGF in prostate tissue and regulate immune function.
4.Analysis of Major Virulence Genes in Vibrio Parahaemolyticus Isolates from Coastal Areas in Zhejiang Province
Peijie JIN ; Beibei WU ; Shuna WANG ; Ying YU ; Yonghua QIAN ; Weihuan FANG
Microbiology 2008;0(07):-
Several aquatic species and their enviroments were examined for presence of Vibrio parahaemo-lyticus between 2007 and 2008 in the coastal areas in Zhejiang province, and some virulence-related genes such as tdh, trh, ureC and vscC2 were investigated from the isolates. V. parahaemolyticus was recovered from 70% of the samples tested (395/566). The genes tdh, trh and ureC existed in 10.1%, 20.0% and 11.1% respectively from 395 isolates. Among the 40 tdh-positive isolates, 32.5% harbored the vscC2 gene, one of the type three secretion system 2 (T3SS2) gene family. Thirty-eight of the 40 tdh-positive isolates were positive for the Kanagawa phenomenon. Out of 44 trh-and-ureC-positive isolates, only six exhibited urease phenotype. Overall, this study reveals the significant prevalence of Vibrio parahaemolyticus in seafoods and their habitats with high diversity of virulence genes. Representative V. parahaemolyticus isolates could beused for further investigation into their pathongenecity, functional genomics, and molecular evolution.
5.Expression of survivin and PCNA in lung cancer cells induced by Gejiu mineral powder.
Rui LIANG ; Kewei JIN ; Zhiqiang WANG ; Zuohui ZHAO ; Fang WANG ; Qian GAO ; Yonghua RUAN
Chinese Journal of Lung Cancer 2007;10(2):83-87
BACKGROUNDGejiu in Yunnan Province is a region where the incidence of lung cancer is high among the miners of tin mine. Our previous research team successfully induced the malignant transformation of immortalized human bronchial epithelial cells (BEAS-2B) by Gejiu mineral powder in vitro. The objective of this study is to explore the role of survivin and proliferating cell nuclear antigen (PCNA) in the pathway of the malignant transformation of BEAS-2B induced by Gejiu mineral powder.
METHODSProtein expression of survivn and PCNA in BEAS-2B cells and its malignant transformation cells was respectively evaluated by immunofluorescence cytochemistry staining technique and immunohistochemistry.
RESULTS(1)The expression of survivin protein was negative in BEAS-2B cells and was positive in its malignant transformation cells by immunofluorescence cytochemistry staining techniques. And the protein level of PCNA was low in BEAS-2B cells and high in its malignant transformation cells. (2)The positive expression of survivin protein in BEAS-2B cells (0/20) was significantly lower than that in its malignant transformation cells (85%, 17/20) by immunohistochemistry (P < 0.001). And the labelling index (LI) of PCNA in BEAS-2B cells was significantly lower than that in its malignant transformation cells (P < 0.001). LI of PCNA in the malignant transformation cells of BEAS-2B with positive expression of survivin was significantly higher than that with negative expression of survivin (P < 0.001).
CONCLUSIONS(1)The up-regulation expression of survivin in malignant transforma- tion cells of BEAS-2B suggests that survivin may play an important role in the pathway of malignant transformation in BEAS-2B cells induced by Gejiu mineral powder. It may give a proof for revealing the carcinogenesis of lung cancer in Gejiu miner. Survivin may be identified as a novel potential diagnostic and therapeutic target of lung cancer in Gejiu miner. (2)The up-regulation expression of PCNA in malignant transformation cells of BEAS-2B suggests that cell proliferation may play an important role in the pathway of malignant transformation. (3)Survivin may promote cell proliferation mediated by PCNA. Survivn and PCNA may play synergetic roles in the process of malignant transformation in BEAS-2B cells induced by Gejiu mineral powder.
6.Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-mono-therapy in patients with ischemic stroke or transient ischemic attack
Cheng YANG ; Jie QIAN ; Xun TANG ; Pei GAO ; Yonghua HU
Chinese Journal of Epidemiology 2015;36(12):1430-1435
Objective To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack.Methods Retrieve randomized controlled trials conformed to the inclusion and exclusion criteria in Cochrane Library,Medline,Embase,and Web of Science electronic database,between January 1,1998 and April 1,2015.Cochrane Collaboration was used to assess the methodological quality of the included research papers.Stratification analysis was performed on factors as:race,subtypes of the disease,duration of follow-up and with or without clopidogrel loading dose,of the patients.Results A total of 7 studies were eligible for analysis,including 14 022 study objects.Data from Meta-analysis showed that dualantiplatelet therapy,when compared to the mono-therapy group,could reduce the risk of recurrent stroke (RR=0.71,95% CI:0.61-0.84,P<0.001),at the same time,increase the risk of bleeding events (RR=1.60,95%CI:1.46-1.76,P<0.001).Data derived from the Hierarchical analysis showed that the risk of stroke recurrence in Chinese population (RR=0.55,95%CI:0.34-0.89) was lower than recorded in other populations (RR=0.78,95%CI:0.66-0.93),with the risks of bleeding events as RR=1.41 (95%CI:1.01-1.96) and RR=1.62(95%CI:1.47-1.79),respectively.Risk of recurrence among the group with clopidogrel loading dose (RR=0.69,95%CI:0.58-0.81) was less than those without (RR=0.74,95%CI:0.56-0.99).The risks of occurrence on bleeding events were RR=1.59 (95%CI:1.10-2.30) and RR=1.60(95%CI:1.46-1.77),respectively.Conclusion The combined therapy of aspirin and clopidogrel could reduce the risk of recurrence of ischemic stroke and TIA patients,but increase the risk of bleeding,when compared to the group that using aspirin alone for the therapy.In Chinese population,the combined therapy seemed more effective than using aspirin alone in reducing the recurrence of stroke,but without increasing the risk of bleeding.
7.Research progress of apoptosis signal regulating kinases-1 and its inhibitors in non-alcoholic steatohepatitis
Lei HAN ; Xiaomeng ZHANG ; Xu QUAN ; Yonghua LEI ; Hai QIAN
Journal of China Pharmaceutical University 2019;50(2):135-142
Non-alcoholic steatohepatitis(NASH)is the most common chronic liver disease. However, the treatment of NASH remains challenging. Apoptosis signal regulating kinases-1(ASK-1)is a member of mitogen-activated protein kinase kinase kinases(MAPKKKs). When the body is stimulated by reactive oxygen species, endoplasmic reticulum stress, calcium influx and extracellular inflammatory signals, c-Jun amino terminal kinases(JNK)and p38 MAPK wiube activated, which then promotes cell proliferation, differentiation, apoptosis and production of inflammatory factors, and causes NASH, fibrosis and other diseases. Therefore, ASK-1 inhibitors can be used to treat NASH. This paper reviews the current treatment methods of NASH, the structure and mechanism of ASK-1, and the research progress of ASK-1 inhibitors in the treatment of NASH in recent years, which aims to explore the guiding significance for the design and development of ASK-1 inhibitors.
8.Consensus for the management of severe acute respiratory syndrome.
Nanshang ZHONG ; Yanqing DING ; Yuanli MAO ; Qian WANG ; Guangfa WANG ; Dewen WANG ; Yulong CONG ; Qun LI ; Youning LIU ; Li RUAN ; Baoyuan CHEN ; Xiangke DU ; Yonghong YANG ; Zheng ZHANG ; Xuezhe ZHANG ; Jiangtao LIN ; Jie ZHENG ; Qingyu ZHU ; Daxin NI ; Xiuming XI ; Guang ZENG ; Daqing MA ; Chen WANG ; Wei WANG ; Beining WANG ; Jianwei WANG ; Dawei LIU ; Xingwang LI ; Xiaoqing LIU ; Jie CHEN ; Rongchang CHEN ; Fuyuan MIN ; Peiying YANG ; Yuanchun ZHANG ; Huiming LUO ; Zhenwei LANG ; Yonghua HU ; Anping NI ; Wuchun CAO ; Jie LEI ; Shuchen WANG ; Yuguang WANG ; Xioalin TONG ; Weisheng LIU ; Min ZHU ; Yunling ZHANG ; Zhongde ZHANG ; Xiaomei ZHANG ; Xuihui LI ; Wei CHEN ; Xuihua XHEN ; Lin LIN ; Yunjian LUO ; Jiaxi ZHONG ; Weilang WENG ; Shengquan PENG ; Zhiheng PAN ; Yongyan WANG ; Rongbing WANG ; Junling ZUO ; Baoyan LIU ; Ning ZHANG ; Junping ZHANG ; Binghou ZHANG ; Zengying ZHANG ; Weidong WANG ; Lixin CHEN ; Pingan ZHOU ; Yi LUO ; Liangduo JIANG ; Enxiang CHAO ; Liping GUO ; Xuechun TAN ; Junhui PAN ; null ; null
Chinese Medical Journal 2003;116(11):1603-1635